Search | Clinical Trials Finder

Conditions: Age-related Macular Degeneration
Interventions: RetnaGene AMD LDT; Device
Lead sponsor: Sequenom, Inc.; Industry
Eligibility: 50 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 3
States / cities: San Francisco, California • Lexington, Kentucky • Nashville, Tennessee

Conditions: Macular Neovascularization Secondary to Age-Related Macular Degeneration
Interventions: 4D-150 IVT (3E10 vg/eye), EYLEA® (aflibercept) Injection 2 mg (0.05mL); Biological
Lead sponsor: 4D Molecular Therapeutics; Industry
Eligibility: 50 Years and older
Enrollment: 480 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 91
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Springdale, Arkansas + 79 more

Conditions: Geographic Atrophy
Interventions: Sham, Lampalizumab; Other · Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 60 Years and older
Enrollment: 96 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 36
States / cities: Mesa, Arizona • Tucson, Arizona • Springdale, Arkansas + 33 more

Conditions: Age-related Macular Degeneration, Diabetic Macular Edema, Injection Site, Injection Site Infection, Pain, Postoperative
Interventions: Proparacaine, Conjunctival culture; Drug · Procedure
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Geographic Atrophy
Interventions: RO7303359; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 50 Years and older
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 12
States / cities: Mountain View, California • Sacramento, California • Santa Maria, California + 9 more

Conditions: Diabetic Macular Edema
Interventions: Ranibizumab 0.3 mg intravitreal injection, Guided Laser Photocoagulation; Drug · Device
Lead sponsor: Palmetto Retina Center, LLC; Other
Eligibility: 18 Years to 100 Years
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2018
U.S. locations: 3
States / cities: Beverly Hills, California • West Columbia, South Carolina • Houston, Texas

Conditions: Vitrectomy
Interventions: Ocriplasmin 25µg, Ocriplasmin 75µg, Ocriplasmin 125µg, Placebo; Drug
Lead sponsor: ThromboGenics; Industry
Eligibility: 18 Years and older
Enrollment: 125 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 20
States / cities: Tucson, Arizona • Huntington Beach, California • Los Angeles, California + 16 more

Conditions: Macular Degeneration, Age-Related, Geographic Atrophy
Interventions: Galegenimab; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 60 Years and older
Enrollment: 144 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 48
States / cities: Bakersfield, California • Encino, California • Fullerton, California + 43 more

Conditions: Age Related Macular Degeneration, Pigment Epithelial Detachment
Interventions: Aflibercept; Drug
Lead sponsor: Tennessee Retina; Other
Eligibility: 50 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 3
States / cities: San Francisco, California • Lexington, Kentucky • Nashville, Tennessee

Conditions: Macular Degeneration, Wet Macular Degeneration
Interventions: Intravitreal aflibercept injection; Drug
Lead sponsor: University of California, San Diego; Other
Eligibility: 50 Years to 90 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2019
U.S. locations: 1
States / cities: La Jolla, California

Conditions: Proliferative Vitreoretinopathy
Interventions: Methotrexate; Drug
Lead sponsor: Stanford University; Other
Eligibility: Up to 18 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Age Related Macular Degeneration
Interventions: Not listed
Lead sponsor: Sequenom, Inc.; Industry
Eligibility: 55 Years and older
Enrollment: 196 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Neovascular Age-related Macular Degeneration (nAMD)
Interventions: SOK583A1; Drug
Lead sponsor: Sandoz; Industry
Eligibility: 50 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022
U.S. locations: 5
States / cities: Poway, California • Marietta, Georgia • Oak Forest, Illinois + 2 more

Conditions: Intravitreal Injection Patients
Interventions: Vigamox; Drug
Lead sponsor: Illinois Retina Associates; Other
Eligibility: 21 Years to 100 Years
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: Harvey, Illinois

Conditions: Diabetic Macular Edema (DME)
Interventions: UBX1325, Sham; Drug · Other
Lead sponsor: Unity Biotechnology, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 19
States / cities: Phoenix, Arizona • Bakersfield, California • Encino, California + 15 more

Conditions: Macular Degeneration
Interventions: JSM6427; Drug
Lead sponsor: Jerini Ophthalmic; Industry
Eligibility: 50 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 9
States / cities: Beverly Hills, California • Boston, Massachusetts • Royal Oak, Michigan + 6 more

Conditions: Nonproliferative Diabetic Retinopathy
Interventions: Intravitreal aflibercept injection [IAI], Sham; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 402 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 71
States / cities: Phoenix, Arizona • Tucson, Arizona • Arcadia, California + 63 more

Conditions: Macular Degeneration, Diabetic Retinopathy, Retinal Vein Occlusion (RVO)
Interventions: Iheezo, Lidocaine pledget; Drug
Lead sponsor: Retina Consultants of Delmarva; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 1
States / cities: Easton, Maryland

Conditions: Cytomegalovirus Retinitis, HIV Infections
Interventions: Fomivirsen sodium, Ganciclovir; Drug
Lead sponsor: Ionis Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 194 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 18
States / cities: Los Angeles, California • Pasadena, California • San Diego, California + 14 more

Conditions: Proliferative Diabetic Retinopathy
Interventions: Brolucizumab 6 mg, Panretinal photocoagulation laser; Biological · Procedure
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 689 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 40
States / cities: Tucson, Arizona • Beverly Hills, California • Fullerton, California + 32 more

Conditions: Retinal Disease
Interventions: IRX-101, Providone-Iodine; Drug
Lead sponsor: iRenix Medical, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 155 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2026
U.S. locations: 7
States / cities: Greenwich, Connecticut • Madison, Mississippi • Erie, Pennsylvania + 4 more

Conditions: AMD (With Persistent or Recurrent Fluid Despite Monthly Intravitreal Anti-VEGF Therapy)
Interventions: Alfilbercept; Drug
Lead sponsor: Vitreous -Retina- Macula Consultants of New York; Other
Eligibility: 50 Years and older
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: New York, New York

Conditions: Geographic Atrophy
Interventions: Lampalizumab, Sham Comparator; Drug · Other
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 50 Years and older
Enrollment: 975 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 67
States / cities: Phoenix, Arizona • Tucson, Arizona • Fullerton, California + 60 more

Conditions: Branch Retinal Vein Occlusion
Interventions: Macular Laser Photocoagulation, Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321); Procedure · Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 183 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 45
States / cities: Phoenix, Arizona • Tucson, Arizona • Beverly Hills, California + 42 more

Search by objective public record fields.

Genetic Load and Phenotype in Aggressive AMD

4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration

A Study of Lampalizumab Intravitreal Injections Administered Every Two Weeks or Every Four Weeks to Participants With Geographic Atrophy

Topical Proparacaine Eye Drops to Improve the Experience of Patients Undergoing Intravitreal Injections

A Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Intravitreal Injections of RO7303359 in Participants With Geographic Atrophy Secondary to Age-related Macular Degeneration

A Safety and Efficacy Trial of a Treat and Extend Protocol Using Ranibizumab With and Without Laser Photocoagulation for Diabetic Macular Edema

A Study of the Safety and Efficacy of Microplasmin to Induce a Posterior Vitreous Detachment (MIVI III)

A Study Assessing the Long-Term Safety and Tolerability of Galegenimab (FHTR2163) in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration

On-label tReatment With Intravitreal Aflibercept injectiOn for Patients With Persistent Pigment epitheliaL Detachments in Neovascular Age Related Macular Degeneration (AMD)

EAGLE: Evaluating Genotypes Using Intravitreal Aflibercept Injection

Methotrexate For The Prevention and Treatment of Proliferative Vitreoretinopathy in Pediatric Patients

Evaluation of the Association Between Genetic Load and Response to Anti-VEGF Therapy in AMD Patients

Study of the Safety of Use of Intravitreal SOK583A1 Provided in a Vial Kit

Dosage Study for Vigamox Eye Drops Prior to Intravitreal Injections

Safety, Tolerability and Evidence of Activity Study of UBX1325 in Patients With Diabetic Macular Edema (BEHOLD)

A Phase 1 Safety Study of Single and Repeated Doses of JSM6427 (Intravitreal Injection) to Treat AMD

Study of the Efficacy and Safety of Intravitreal (IVT) Aflibercept for the Improvement of Moderately Severe to Severe Nonproliferative Diabetic Retinopathy (NPDR)

Patient Comfort Following Intravitreal Injections Using Iheezo Versus Standard Anesthesia

A Randomized Comparison of Intravitreal ISIS 2922 Plus Ganciclovir Versus Ganciclovir as Treatment for Patients With Cytomegalovirus Retinitis ( CMVR )

Study of Efficacy and Safety of Brolucizumab Versus Panretinal Photocoagulation Laser in Patients With Proliferative Diabetic Retinopathy

SteRilizing Eye SoLution to ImprovE Patient ComFort (RELIEF)

To Evaluate The Role of Intravitreal Aflibercept Injection (2.0 mg) in the Management of Previously Treated Patients With Exudative AMD

A Study Investigating the Safety and Efficacy of Lampalizumab Intravitreal Injections in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration

Study to Assess the Clinical Efficacy and Safety of Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321) in Patients With Branch Retinal Vein Occlusion (BRVO)